|
Avila Therapeutics Signs Agreement with Novartis to Develop Novel Covalent Drug Candidate
|
Wireless News
08-03-2009
Avila Therapeutics Signs Agreement with Novartis to Develop Novel Covalent Drug Candidate
Type: News
Avila Therapeutics, Inc., a biotechnology company, announced that it has entered into an option agreement with the Novartis Option Fund focused on Avila's advancement of a novel covalent drug program from Avila's research pipeline in conjunction with an equity investment.
The agreement includes upfront and potential milestones payments to Avila totaling over $200 million plus royalties. Avila's covalent drugs offer the potential to treat many serious diseases through ...
Find more facts and information related to the
article "Avila Therapeutics Signs Agreement with Novartis ..."